Looking for the next Amazon or Tesla to invest at the Start?

Looking for the next Amazon or Tesla to invest at the Start?

CRISPR Therapeutics - revenue projection = Massive

I am accumulating shares. you may want to start looking into CrSp.Let's calculate the revenue potential for CRISPR Therapeutics based on their approved therapy and pipeline:

THERAPY 1: BEING ROLLED OUT AND APPROVED IN THE USA AND EUROPE

Casgevy (approved for sickle cell disease and beta-thalassemia):

Price per therapy: $2.2 million

Potential patient pool: 70 million

Assuming 2% adoption: 1.4 million patients

Potential revenue: $3.08 trillion

THERAPY 2:

CTX310 (Phase 1 for cardiovascular disease):

Assuming similar pricing and 1% adoption of global cardiovascular patients (520 million)Potential revenue: $1.144 trillion

THERAPY 3:

CTX320 (Phase 1 for elevated Lp(a)):20% of global population has elevated Lp(a), assuming 0.5% adoption

Potential revenue: $1.716 trillion

THERAPY 4:

CTX340 and CTX450 (preclinical):

Assuming more modest adoption due to earlier stage, estimate $500 billion each.Combined potential revenue: $1 trillion

Total potential revenue: $6.94 trillion

ASSUMPTION OF REVENUE POTENTIAL DISCOUNTED TO NET PRESENT VALUE AND THEN CALCULATION OF SHARE PRICE ASSUMPTION GIVEN THIS DATA:

Assuming this revenue is spread over 10 years and using a conservative 10% discount rate for NPV calculation:NPV = $6.94 trillion / (1.1^5) ≈ $4.31 trillion

CRISPR Therapeutics has approximately 79 million shares outstanding.Value per share: $4.31 trillion / 79 million ≈ $54,557

Projected share price (multiplied by 25, 25 is the mlptiple at which companies trade on average): $1,363,925

This calculation suggests an extremely high potential value, but it's important to note that this is a highly optimistic scenario.

When people g back to see how they would have done with Amazon or Netflix, well here you have another technology company that can very well outdo them all.

Short Interest: 19.39 million shares

Float: Approximately 83.94 million shares (calculated from 23.10% of float shorted)

Cash: $2.0 billion as of June 2024

Growth Rate: Revenue growth of 19% over the past year

Debt: Zero debt reported

Volume: Average trading volume of 1.48 million shares per day

Days to Cover: 14.8 days

Additional information:

Short Interest Ratio: 13.31 Days to Cover

Short Interest % of Float: 23.10%5

Cash Burn: $129 million in the last year

Cash Runway: Several years based on current burn rate

Market Capitalization: Approximately $4.2-$4.3 billion

The P/E ratio is not provided in the search results, which is common for biotechnology companies that may not yet have consistent earnings.

THE PERFECT CANDIDATE FOR A MASSIVE SHORT SQUEEZE.


#investments, #CRSP, #Crispr, #Therapy, #Therapeutics, #Get, #Rich, #Biotech, #Technology, #Medicine, #SickelCell
link to article: "https://www.linkedin.com/pulse/looking-next-amazon-tesla-invest-very-beginning-well-read-s-sc-n--0r8be/?trackingId=o%2B1DocTdTi%2BO%2Bwk%2FqKV1yA%3D%3D"

Read More

Share:

Latest News